Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, Jiangsu, China.
Int J Cancer. 2022 Nov 15;151(10):1654-1662. doi: 10.1002/ijc.34139. Epub 2022 Jun 13.
Oncolytic viruses (OVs) represent a class of cancer immunotherapies that rely on hijacking the host cell factory for replicative oncolysis and eliciting immune responses for tumor clearance. An increasing evidence suggests that the metabolic state of tumor cells and immune cells is a putative determinant of the efficacy of cancer immunotherapy. However, how therapeutic intervention with OVs affects metabolic fluxes within the tumor microenvironment (TME) remains poorly understood. Herein, we review the complexities of metabolic reprogramming involving the effects of viruses and their consequences on tumor cells and immune cells. We highlight the inherent drawback of oncolytic virotherapy, namely that treatment with OVs inevitably further exacerbates the depletion of nutrients and the accumulation of metabolic wastes in the TME, leading to a metabolic barrier to antitumor immune responses. We also describe targeted metabolic strategies that can be used to unlock the therapeutic potential of OVs.
溶瘤病毒（OVs）代表了一类癌症免疫疗法，它们依赖于劫持宿主细胞工厂进行复制性溶瘤，并引发免疫反应以清除肿瘤。越来越多的证据表明，肿瘤细胞和免疫细胞的代谢状态是癌症免疫疗法疗效的一个潜在决定因素。然而，OVs 的治疗干预如何影响肿瘤微环境（TME）中的代谢通量仍知之甚少。本文综述了涉及病毒作用及其对肿瘤细胞和免疫细胞影响的代谢重编程的复杂性。我们强调了溶瘤病毒疗法固有的缺陷，即 OVs 的治疗不可避免地进一步加剧了 TME 中营养物质的消耗和代谢废物的积累，导致抗肿瘤免疫反应的代谢障碍。我们还描述了可以用于释放 OVs 治疗潜力的靶向代谢策略。
